A $1,000 investment in Moderna (MRNA) stock made roughly one week earlier has risen to approximately $2,740 following a dramatic single-day surge. Shares more than doubled on the back of positive late-stage cancer vaccine trial results.
The move ranks among the largest one-day gains in the stock’s history.
The Drivers of This Activity
On 19 August 2026, Moderna closed at $174.38, up 176.97% from the previous day’s close near $63. About one week earlier, on 13 August, the stock closed around $63.65. That price appreciation turns a $1,000 position into roughly $2,740 before fees and taxes.
The catalyst was positive Phase 3 data for Moderna’s personalized mRNA cancer vaccine (intismeran) used in combination with Merck’s Keytruda. The trial, involving more than 1,100 patients with high-risk melanoma that had been surgically removed, met its primary endpoint by significantly extending the time patients lived without the cancer returning compared with Keytruda alone. It also reduced the risk of the disease spreading.
Merck shares also rose sharply on the news. Analysts described the result as an important validation of the mRNA platform in oncology.
Impact and Broader Context
The surge dramatically increased Moderna’s market value and reignited investor interest in mRNA-based cancer therapies. It also lifted sentiment around the broader biotech sector and personalized medicine approaches.
While the one-day move produced outsized short-term gains for recent buyers, the stock remains highly volatile and sensitive to clinical, regulatory and competitive developments. Full detailed trial data are expected to be presented at an upcoming medical meeting, which could further influence the shares.
Investors will watch subsequent price action, any updates on regulatory pathways, and whether the positive melanoma results translate into progress in other cancer indications.
Source: Stock price data from multiple providers including StockAnalysis and MarketWatch; Axios; CNBC
Moderna and Merck Phase 3 trial announcement and contemporaneous market data